Ruxolitinib Cream for Acute Skin GVHD

This trial tests a cream called ruxolitinib to determine its safety for treating acute graft versus host disease (GVHD), a skin condition that can occur after a stem cell transplant, causing redness and itching. The cream is applied directly to the skin twice a day. Suitable participants have undergone a stem cell transplant, are experiencing acute skin GVHD, and are not using other immune-suppressing medications. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this new treatment.

Studies have shown that ruxolitinib cream is generally safe for people with skin conditions like graft-versus-host disease (GVHD). In previous research, ruxolitinib cream was compared to a placebo (a substance with no active ingredients), and participants using the cream experienced fewer skin rashes and sores. Importantly, those studies reported no serious side effects, confirming its safety.

Ruxolitinib blocks certain proteins called Janus Kinase (JAK) 1/2, which are involved in inflammation, thereby reducing skin problems. Other studies have found the cream to be well-tolerated, with only mild and manageable side effects.

Unlike the standard treatments for acute skin graft-versus-host disease (GVHD), which typically involve systemic immunosuppressants and steroids, Ruxolitinib cream offers a targeted, topical approach. This treatment is unique because it contains Ruxolitinib, a JAK inhibitor, which works by blocking specific proteins involved in the inflammatory process. Applying the cream directly to the skin allows it to act precisely where needed, potentially reducing the side effects commonly associated with systemic therapies. Researchers are excited about this approach as it may provide relief from symptoms like erythroderma and pruritus more quickly and with fewer systemic complications.

Research has shown that ruxolitinib cream can help treat skin problems caused by graft-versus-host disease (GVHD). In earlier studies, patients using this cream experienced noticeable improvements in skin rashes and sores. One study found that after 28 days, the cream reduced the affected skin area by 57%, while a placebo cream only reduced it by 28%. Another study demonstrated that the cream worked well for both soft and slightly hardened skin issues. Overall, these results suggest that ruxolitinib cream, which participants in this trial will apply topically, may help ease skin problems in people with GVHD.¹²⁴⁵⁶